INT104493

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.53
First Reported 2002
Last Reported 2011
Negated 3
Speculated 0
Reported most in Abstract
Documents 56
Total Number 58
Disease Relevance 27.76
Pain Relevance 16.86

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Mapk8) signal transduction (Mapk8) mitochondrion (Mapk8)
nucleus (Mapk8) kinase activity (Mapk8) cytoplasm (Mapk8)
Anatomy Link Frequency
lung 5
hepatocytes 3
liver 2
brain 2
nerve 2
Mapk8 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Neuropathic pain 61 100.00 Very High Very High Very High
Paracetamol 42 100.00 Very High Very High Very High
cINOD 13 99.92 Very High Very High Very High
dexamethasone 5 99.74 Very High Very High Very High
Inflammation 317 99.42 Very High Very High Very High
Kinase C 45 99.20 Very High Very High Very High
ischemia 194 99.12 Very High Very High Very High
anesthesia 40 99.12 Very High Very High Very High
Pain 37 99.12 Very High Very High Very High
intrathecal 8 99.02 Very High Very High Very High
Disease Link Frequency Relevance Heat
Neuropathic Pain 80 100.00 Very High Very High Very High
Diabetes Mellitus 11 100.00 Very High Very High Very High
Apoptosis 252 99.90 Very High Very High Very High
Injury 165 99.82 Very High Very High Very High
Adult Respiratory Distress Syndrome 206 99.80 Very High Very High Very High
Targeted Disruption 19 99.44 Very High Very High Very High
Pneumonia 34 99.42 Very High Very High Very High
Nervous System Injury 20 99.42 Very High Very High Very High
INFLAMMATION 414 99.20 Very High Very High Very High
Cv Unclassified Under Development 96 99.12 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thus, G. elata prevents serum-deprived apoptosis through activation of the serine/threonine kinase-dependent pathway and suppression of JNK activity.
Negative_regulation (suppression) of JNK associated with apoptosis
1) Confidence 0.53 Published 2004 Journal Life Sci. Section Abstract Doc Link 15261768 Disease Relevance 0.76 Pain Relevance 0.07
Pretreatment with neutralizers or inhibitors of NO and JNK may exert a neuroprotective effect in this regard.
Negative_regulation (inhibitors) of JNK
2) Confidence 0.43 Published 2006 Journal Synapse Section Abstract Doc Link 16284960 Disease Relevance 0.29 Pain Relevance 0.45
Hemodynamic effects of potent and selective JNK inhibitors in anesthetized rats: implication for targeting protein kinases in metabolic diseases.
Negative_regulation (inhibitors) of JNK associated with metabolic disorder and anesthesia
3) Confidence 0.43 Published 2007 Journal Bioorg. Med. Chem. Lett. Section Title Doc Link 17055723 Disease Relevance 0.10 Pain Relevance 0.10
Pre-treatment as well as post-treatment of rats with a JNK inhibitor, SP600125, significantly attenuated thermal hyperalgesia, as assessed by paw-withdrawal latency, and the upregulation of c-fos immunoreactivity in dorsal horn neurons.
Negative_regulation (inhibitor) of JNK in neurons associated with thermal hyperalgesia, dorsal horn neuron and withdrawal
4) Confidence 0.43 Published 2005 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 16055088 Disease Relevance 1.33 Pain Relevance 0.98
SP600125, a selective inhibitor of JNK, significantly attenuated morphine tolerance.
Negative_regulation (inhibitor) of JNK associated with tolerance and morphine
5) Confidence 0.43 Published 2009 Journal Neurosci. Lett. Section Abstract Doc Link 19818835 Disease Relevance 0 Pain Relevance 1.61
We found that the PCNA levels were significantly reduced after pretreatment with inhibitors of ERK1/2, JNK1/2, and P38 (Figure 4(c)).
Negative_regulation (inhibitors) of JNK
6) Confidence 0.42 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2997511 Disease Relevance 0 Pain Relevance 0.03
Phosphorylation of c-Jun N-terminal kinase (JNK) in sensory neurones of diabetic rats, with possible effects on nerve conduction and neuropathic pain: prevention with an aldose reductase inhibitor.
Negative_regulation (prevention) of JNK in nerve associated with pain, diabetes mellitus and neuropathic pain
7) Confidence 0.42 Published 2006 Journal Diabetologia Section Title Doc Link 16456679 Disease Relevance 0.30 Pain Relevance 0.30
Here, we observed that sepsis led to serine phosphorylation of IRS-1 and that atorvastatin reversed this phenomenon in three target tissues, in parallel with a reduction in JNK activity.
Negative_regulation (reduction) of JNK associated with sepsis
8) Confidence 0.41 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2997789 Disease Relevance 1.19 Pain Relevance 0.14
Among the potential molecular targets by which celecoxib may regulate FAS expression, only c-Jun N-terminal kinase-1 (JNK1) was significantly down-regulated.
Negative_regulation (down-regulated) of c-Jun N-terminal kinase-1
9) Confidence 0.40 Published 2007 Journal Exp. Biol. Med. (Maywood) Section Abstract Doc Link 17463161 Disease Relevance 0.22 Pain Relevance 0.12
Celecoxib decreases fatty acid synthase expression via down-regulation of c-Jun N-terminal kinase-1.
Negative_regulation (down-regulation) of c-Jun N-terminal kinase-1
10) Confidence 0.40 Published 2007 Journal Exp. Biol. Med. (Maywood) Section Title Doc Link 17463161 Disease Relevance 0.25 Pain Relevance 0.20
Furthermore, a known inhibitor of JNK suppressed FAS expression in rat hepatocytes.
Negative_regulation (inhibitor) of JNK in hepatocytes
11) Confidence 0.40 Published 2007 Journal Exp. Biol. Med. (Maywood) Section Abstract Doc Link 17463161 Disease Relevance 0.21 Pain Relevance 0.11
Although JNK and p38 inhibitors attenuated their related enzyme activities during serum deprivation, only JNK inhibitor prevented serum-deprived apoptosis.
Negative_regulation (inhibitors) of JNK associated with apoptosis
12) Confidence 0.39 Published 2004 Journal Life Sci. Section Abstract Doc Link 15261768 Disease Relevance 0.72 Pain Relevance 0.08
To explore a new therapeutic strategy for preventing the occurrence of LPS-induced lung inflammation and injury, we attempted to inhibit JNK or ERK activity by pretreatment with a selective JNK inhibitor, SP600125, or a specific inhibitor of MEK/ERK, PD98059, 1 hour before LPS treatment.
Negative_regulation (inhibit) of JNK in lung associated with inflammation, injury and pneumonia
13) Confidence 0.38 Published 2004 Journal Respir Res Section Body Doc Link PMC538282 Disease Relevance 0.77 Pain Relevance 0.15
To explore a new therapeutic strategy for preventing the occurrence of LPS-induced lung inflammation and injury, we attempted to inhibit JNK or ERK activity by pretreatment with a selective JNK inhibitor, SP600125, or a specific inhibitor of MEK/ERK, PD98059, 1 hour before LPS treatment.
Negative_regulation (inhibitor) of JNK in lung associated with inflammation, injury and pneumonia
14) Confidence 0.38 Published 2004 Journal Respir Res Section Body Doc Link PMC538282 Disease Relevance 0.78 Pain Relevance 0.16
Recently, it has been demonstrated that JNK inhibition by SP600125, in both ischemia and reperfusion periods, almost completely suppressed TNF?
Negative_regulation (inhibition) of JNK associated with ischemia
15) Confidence 0.38 Published 2004 Journal Respir Res Section Body Doc Link PMC538282 Disease Relevance 1.05 Pain Relevance 0.36
The hemodynamic effects of a series of potent and selective 4-aminopyridine carboxamide-based pan-JNK inhibitors were assessed in an anesthetized rat model.
Negative_regulation (inhibitors) of pan-JNK
16) Confidence 0.38 Published 2007 Journal Bioorg. Med. Chem. Lett. Section Abstract Doc Link 17055723 Disease Relevance 0.07 Pain Relevance 0
However, inhibition of ERK 1/2 and JNK had no effect on ethanoland acetaldehyde-induced alpha-SMA expression in PSCs.
Negative_regulation (inhibition) of JNK in PSCs
17) Confidence 0.36 Published 2003 Journal Pancreas Section Body Doc Link 12883264 Disease Relevance 0 Pain Relevance 0
However, total JNK levels were down-regulated.
Negative_regulation (down-regulated) of JNK
18) Confidence 0.33 Published 2008 Journal Neurotoxicology Section Abstract Doc Link 18845185 Disease Relevance 0.22 Pain Relevance 0.27
BDNF-induced LTP was completely abolished by the protein synthesis inhibitor (anisomycin), by N-methyl-D-aspartate (NMDA) receptor blocker (MK-801), by extracellular signal-regulated protein kinase (ERK) inhibitor (PD98059) or by p38 mitogen-activated protein kinase (MAPK) inhibitor (SB203580) but not by c-Jun N-terminal kinase (JNK) inhibitor (SP600125).
Neg (not) Negative_regulation (inhibitor) of c-Jun N-terminal kinase associated with long-term potentiation
19) Confidence 0.32 Published 2008 Journal Exp. Neurol. Section Abstract Doc Link 18565512 Disease Relevance 0.15 Pain Relevance 0.90
BDNF-induced LTP was completely abolished by the protein synthesis inhibitor (anisomycin), by N-methyl-D-aspartate (NMDA) receptor blocker (MK-801), by extracellular signal-regulated protein kinase (ERK) inhibitor (PD98059) or by p38 mitogen-activated protein kinase (MAPK) inhibitor (SB203580) but not by c-Jun N-terminal kinase (JNK) inhibitor (SP600125).
Neg (not) Negative_regulation (inhibitor) of JNK associated with long-term potentiation
20) Confidence 0.32 Published 2008 Journal Exp. Neurol. Section Abstract Doc Link 18565512 Disease Relevance 0.15 Pain Relevance 0.89

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox